Antivirals and resistance: Influenza virus

Current Opinion in Virology

Volumn 1, Issue 6, 2011, Pages 563-573

  Ison, Michael G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; DAS 181; FAVIPIRAVIR; FLUDASE; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; LANINAMIVIR; LANINAMIVIR OCTANOATE; OSELTAMIVIR; PERAMIVIR; RIBAVIRIN; RIMANTADINE; UNCLASSIFIED DRUG; ZANAMIVIR;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ARTICLE; AUTOMUTILATION; BRONCHITIS; BRONCHOSPASM; CLINICAL TRIAL (TOPIC); COUGHING; DELIRIUM; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; EPIDEMIC; FACE EDEMA; HEADACHE; HUMAN; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; LUNG FUNCTION; MOUTH EDEMA; NAUSEA; NONHUMAN; NOSE INFECTION; PHARYNGITIS; PHARYNX DISEASE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; UNSPECIFIED SIDE EFFECT; VIRUS MUTANT; VIRUS RESISTANCE; VOMITING;

EID: 82955235541     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.09.002     Document Type: Review

References (113)

1. F.G. Hayden, and P. Palese Influenza virus D.D. Richman, R.J. Whitley, F.G. Hayden, Clinical Virology - 3rd edition 2009 ASM Press 943 976
2. R.J. Garten, C.T. Davis, C.A. Russell, B. Shu, S. Lindstrom, A. Balish, W.M. Sessions, X. Xu, E. Skepner, and V. Deyde Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans Science 325 2009 197 201
3. G.J. Smith, D. Vijaykrishna, J. Bahl, S.J. Lycett, M. Worobey, O.G. Pybus, S.K. Ma, C.L. Cheung, J. Raghwani, and S. Bhatt Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic Nature 459 2009 1122 1125
4. W.W. Thompson, D.K. Shay, E. Weintraub, L. Brammer, C.B. Bridges, N.J. Cox, and K. Fukuda Influenza-associated hospitalizations in the United States JAMA 292 2004 1333 1340 (Pubitemid 39223224)
5. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR. Morbidity and Mortality Weekly Report 2010, 59:1057-1062.
6. L.H. Pinto, and R.A. Lamb The M2 proton channels of influenza A and B viruses The Journal of Biological Chemistry 281 2006 8997 9000 (Pubitemid 43864610)
7. T. Jefferson, V. Demicheli, C. Di Pietrantonj, and D. Rivetti Amantadine and rimantadine for influenza A in adults Cochrane Database of Systematic Reviews 2006 CD001169
8. A.E. Fiore, A. Fry, D. Shay, L. Gubareva, J.S. Bresee, and T.M. Uyeki Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR. Recommendations and Reports 60 2011 1 24
9. A. Moscona Neuraminidase inhibitors for influenza The New England Journal of Medicine 353 2005 1363 1373 (Pubitemid 41362704)
10. M.N. Matrosovich, T.Y. Matrosovich, T. Gray, N.A. Roberts, and H.D. Klenk Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium Journal of Virology 78 2004 12665 12667 (Pubitemid 39458784)
11. P.M. Colman, J.N. Varghese, and W.G. Laver Structure of the catalytic and antigenic sites in influenza virus neuraminidase Nature 303 1983 41 44 (Pubitemid 13125071)
12. J.N. Varghese, W.G. Laver, and P.M. Colman Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution Nature 303 1983 35 40 (Pubitemid 13125070)
13. W.R. Taylor, B.N. Thinh, G.T. Anh, P. Horby, H. Wertheim, N. Lindegardh, M.D. de Jong, K. Stepniewska, T.T. Hanh, and N.D. Hien Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza PLoS ONE 3 2008 e3410
14. C. Giraud, S. Manceau, M. Oualha, H. Chappuy, A. Mogenet, P. Duchene, S. Ducrocq, P. Hubert, and J.M. Treluyer High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit Antimicrobial Agents and Chemotherapy 55 2011 433 435
15. E.D. Wildschut, M. de Hoog, M.J. Ahsman, D. Tibboel, A.D. Osterhaus, and P.L. Fraaij Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support PLoS ONE 5 2010 e10938
16. N. Lee, P.K. Chan, D.S. Hui, T.H. Rainer, E. Wong, K.W. Choi, G.C. Lui, B.C. Wong, R.Y. Wong, and W.Y. Lam Viral loads and duration of viral shedding in adult patients hospitalized with influenza The Journal of Infectious Diseases 200 2009 492 500
17. N. Lee, P.K. Chan, G.C. Lui, B.C. Wong, W.W. Sin, K.W. Choi, R.Y. Wong, E.L. Lee, A.C. Yeung, and K.L. Ngai Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? The Journal of Infectious Diseases 203 2011 1739 1747
18. N. Lee, K.W. Choi, P.K. Chan, D.S. Hui, G.C. Lui, B.C. Wong, R.Y. Wong, W.Y. Sin, W.M. Hui, and K.L. Ngai Outcomes of adults hospitalised with severe influenza Thorax 65 2010 510 515
19. S. Jain, L. Kamimoto, A.M. Bramley, A.M. Schmitz, S.R. Benoit, J. Louie, D.E. Sugerman, J.K. Druckenmiller, K.A. Ritger, and R. Chugh Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009 The New England Journal of Medicine 361 2009 1935 1944
20. J. Skarbinski, S. Jain, A. Bramley, E.J. Lee, J. Huang, D. Kirschke, A. Stone, T. Wedlake, S.M. Richards, and S. Page Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States - September-October 2009 Clinical Infectious Diseases 52 Suppl. 1 2011 S50 S59
21. D. Viasus, J.R. Pano-Pardo, J. Pachon, M. Riera, F. Lopez-Medrano, A. Payeras, M.C. Farinas, A. Moreno, J. Rodriguez-Bano, and J.A. Oteo Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A (H1N1) virus infection Chest 2011 10.1378/chest.10-2792 [epub ahead of print]
22. A. Rodriguez, E. Diaz, I. Martin-Loeches, A. Sandiumenge, L. Canadell, J.J. Diaz, J.C. Figueira, A. Marques, F. Alvarez-Lerma, and J. Valles Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A The Journal of Antimicrobial Chemotherapy 66 2011 1140 1149
23. A. McGeer, K.A. Green, A. Plevneshi, A. Shigayeva, N. Siddiqi, J. Raboud, and D.E. Low Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada Clinical Infectious Diseases 45 2007 1568 1575 (Pubitemid 351411840)
24. A.R. Falsey, Y. Murata, and E.E. Walsh Impact of rapid diagnosis on management of adults hospitalized with influenza Archives of Internal Medicine 167 2007 354 360 (Pubitemid 46333935)
25. Y. Murata, E.E. Walsh, and A.R. Falsey Pulmonary complications of interpandemic influenza A in hospitalized adults The Journal of Infectious Diseases 195 2007 1029 1037 (Pubitemid 46452109)
26. E.E. Walsh, C. Cox, and A.R. Falsey Clinical features of influenza A virus infection in older hospitalized persons Journal of the American Geriatrics Society 50 2002 1498 1503 (Pubitemid 35024641)
27. N. Lee, P.K. Chan, K.W. Choi, G. Lui, B. Wong, C.S. Cockram, D.S. Hui, R. Lai, J.W. Tang, and J.J. Sung Factors associated with early hospital discharge of adult influenza patients Antiviral Therapy 12 2007 501 508 (Pubitemid 47041148)
28. N. Lee, P.K. Chan, C.K. Wong, K.T. Wong, K.W. Choi, G.M. Joynt, P. Lam, M.C. Chan, B.C. Wong, and G.C. Lui Viral clearance and inflammatory response patterns in adults hospitalized for pandemic 2009 influenza A(H1N1) virus pneumonia Antiviral Therapy 16 2011 237 247
29. M.G. Ison, M.D. de Jong, K.J. Gilligan, E.S. Higgs, A.T. Pavia, J. Pierson, and F.G. Hayden End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease The Journal of Infectious Diseases 201 2010 1654 1662
30. M.G. Ison Influenza, including the novel H1N1, in organ transplant patients Current Opinion in Infectious Diseases 23 2010 365 373
31. D. Kumar, M.G. Michaels, M.I. Morris, M. Green, R.K. Avery, C. Liu, L. Danziger-Isakov, V. Stosor, M. Estabrook, and S. Gantt Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study The Lancet Infectious Diseases 10 2010 521 526
32. D. Kumar, M.I. Morris, C.N. Kotton, S.A. Fischer, M.G. Michaels, U. Allen, E.A. Blumberg, M. Green, A. Humar, and M.G. Ison Guidance on novel influenza A/H1N1 in solid organ transplant recipients American Journal of Transplantation 10 2010 18 25
33. J. Zaia, L. Baden, M.J. Boeckh, S. Chakrabarti, H. Einsele, P. Ljungman, G.B. McDonald, and H. Hirsch Viral disease prevention after hematopoietic cell transplantation Bone Marrow Transplantation 44 2009 471 482
34. A.P. Campbell, S.T. Jacob, J. Kuypers, A. Wald, J.A. Englund, L. Corey, and M. Boeckh Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir Annals of Internal Medicine 152 2010 619 620
35. M.G. Ison, A. Sharma, J.A. Shepard, J.C. Wain, and L.C. Ginns Outcome of influenza infection managed with oseltamivir in lung transplant recipients The Journal of Heart and Lung Transplantation 27 2008 282 288 (Pubitemid 351375106)
36. D. Vu, A.J. Peck, W.G. Nichols, C. Varley, J.A. Englund, L. Corey, and M. Boeckh Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study Clinical Infectious Disease 45 2007 187 193 (Pubitemid 47041009)
37. S.P. Watcharananan, T. Suwatanapongched, P. Wacharawanichkul, W. Chantratitaya, V. Mavichak, and S.B. Mossad Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposure Transplant Infectious Disease 12 2010 127 131
38. M.G. Ison, and H.H. Hirsch Influenza: a recurrent challenge to transplantation Transplant Infectious Disease 12 2010 95 97
39. N. Khanna, I. Steffen, J.D. Studt, A. Schreiber, T. Lehmann, M. Weisser, U. Fluckiger, A. Gratwohl, J. Halter, and H.H. Hirsch Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation Transplant Infectious Disease 11 2009 100 105
40. B. Donner, V. Niranjan, and G. Hoffmann Safety of oseltamivir in pregnancy: a review of preclinical and clinical data Drug Safety 33 2010 631 642
41. 2009 pandemic influenza A (H1N1) in pregnant women requiring intensive care - New York City, 2009. MMWR. Morbidity and Mortality Weekly Report 2010, 59:321-326.
42. M. Cervantes-Gonzalez, and O. Launay Pandemic influenza A (H1N1) in pregnant women: impact of early diagnosis and antiviral treatment Expert Review of Anti-infective Therapy 8 2010 981 984
43. A.A. Creanga, T.F. Johnson, S.B. Graitcer, L.K. Hartman, T. Al-Samarrai, A.G. Schwarz, S.Y. Chu, J.E. Sackoff, D.J. Jamieson, and A.D. Fine Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women Obstetrics and Gynecology 115 2010 717 726
44. T. Tanaka, K. Nakajima, A. Murashima, F. Garcia-Bournissen, G. Koren, and S. Ito Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women CMAJ 181 2009 55 58
45. L. Yates, M. Pierce, S. Stephens, A.C. Mill, P. Spark, J.J. Kurinczuk, M. Valappil, P. Brocklehurst, S.H. Thomas, and M. Knight Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant Health Technology Assessment 14 2010 109 182
46. R.H. Beigi, K. Han, R. Venkataramanan, G.D. Hankins, S. Clark, M.F. Hebert, T. Easterling, A. Zajicek, Z. Ren, and D.R. Mattison Pharmacokinetics of oseltamivir among pregnant and nonpregnant women American Journal of Obstetrics and Gynecology 204 2011 S84 S88
47. L.G. Greer, R.D. Leff, V.L. Rogers, S.W. Roberts, G.H. McCracken Jr., G.D. Wendel Jr., and J.S. Sheffield Pharmacokinetics of oseltamivir according to trimester of pregnancy American Journal of Obstetrics and Gynecology 204 2011 S89 S93
48. K.C. Worley, S.W. Roberts, and R.E. Bawdon The metabolism and transplacental transfer of oseltamivir in the ex vivo human model Infectious Diseases in Obstetrics and Gynecology 2008 2008 927574
49. T. Svensson, F. Granath, O. Stephansson, and H. Kieler Birth outcomes among women exposed to neuraminidase inhibitors during pregnancy Pharmacoepidemiology and Drug Safety 2011 10.1002/pds.2194 [epub ahead of print]
50. L.G. Greer, J.S. Sheffield, V.L. Rogers, S.W. Roberts, D.D. McIntire, and G.D. Wendel Jr. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications Obstetrics and Gynecology 115 2010 711 716
51. T. Oluyomi-Obi, L. Avery, C. Schneider, A. Kumar, S. Lapinsky, S. Menticoglou, and R. Zarychanski Perinatal and maternal outcomes in critically ill obstetrics patients with pandemic H1N1 Influenza A Journal of Obstetrics and Gynaecology Canada 32 2010 443 447 448-452
52. M. Schatz, C.D. Chambers, K.L. Jones, C. Louik, and A.A. Mitchell Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System American Journal of Obstetrics and Gynecology 204 2011 S64 S68
53. P. Diggory, C. Fernandez, A. Humphrey, V. Jones, and M. Murphy Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial BMJ 322 2001 577 579 (Pubitemid 32234531)
54. L.M. Cass, C. Efthymiopoulos, and A. Bye Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers Clinical Pharmacokinetics 36 Suppl. 1 1999 1 11 (Pubitemid 29322452)
55. J.S. Oxford Antivirals for the treatment and prevention of epidemic and pandemic influenza Influenza and Other Respiratory Viruses 1 2007 27 34
56. R.S. Fritz, F.G. Hayden, D.P. Calfee, L.M. Cass, A.W. Peng, W.G. Alvord, W. Strober, and S.E. Straus Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment The Journal of Infectious Diseases 180 1999 586 593 (Pubitemid 29411341)
57. P.L. Fraaij, E. van der Vries, M.F. Beersma, A. Riezebos-Brilman, H.G. Niesters, A.A. van der Eijk, M.D. de Jong, D. Reis Miranda, A.M. Horrevorts, and B.U. Ridwan Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection The Journal of Infectious Diseases 204 2011 777 782
58. L. Wijaya, Y.Y. Chua, L. Cui, K. Chan, and B.H. Tan Intravenous zanamivir in critically ill patients due to pandemic 2009 (H1N1) influenza A virus Singapore Medical Journal 52 2011 481 485
59. S. Busani, M. Girardis, E. Biagioni, A. Pasetto, and V. Sambri Surfactant therapy and intravenous zanamivir in severe respiratory failure due to persistent influenza A/H1N1 2009 virus infection American Journal of Respiratory and Critical Care Medicine 182 2010 1334
60. C. Dohna-Schwake, B. Schweiger, U. Felderhoff-Muser, M. Fiedler, G.M. Kaiser, A. Paul, P. Gerner, E. Lainka, and P.F. Hoyer Severe H1N1 infection in a pediatric liver transplant recipient treated with intravenous zanamivir: efficiency and complications Transplantation 90 2010 223 224
61. D.E. Dulek, J.V. Williams, C.B. Creech, A.K. Schulert, H.A. Frangoul, J. Domm, M.R. Denison, and J.D. Chappell Use of intravenous zanamivir after development of oseltamivir resistance in a critically Ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus Clinical Infectious Diseases 50 2010 1493 1496
62. G. Harter, O. Zimmermann, L. Maier, A. Schubert, T. Mertens, P. Kern, and J. Wohrle Intravenous zanamivir for patients with pneumonitis due to pandemic (H1N1) 2009 influenza virus Clinical Infectious Diseases 50 2010 1249 1251
63. A.H. Gaur, B. Bagga, S. Barman, R. Hayden, A. Lamptey, J.M. Hoffman, D. Bhojwani, P.M. Flynn, E. Tuomanen, and R. Webby Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza The New England Journal of Medicine 362 2010 88 89
64. I.M. Kidd, J. Down, E. Nastouli, R. Shulman, P.R. Grant, D.C. Howell, and M. Singer H1N1 pneumonitis treated with intravenous zanamivir Lancet 374 2009 1036
65. C. Renaud, A.A. Boudreault, J. Kuypers, K.H. Lofy, L. Corey, M.J. Boeckh, and J.A. Englund H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients Emerging Infectious Diseases 17 2011 653 660 quiz 765
66. H. Ishizuka, S. Yoshiba, H. Okabe, and K. Yoshihara Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers Journal of Clinical Pharmacology 50 2010 1319 1329
67. M. Yamashita Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza Antiviral Chemistry & Chemotherapy 21 2010 71 84
68. N. Sugaya, and Y. Ohashi Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection Antimicrobial Agents and Chemotherapy 54 2010 2575 2582
69. A. Watanabe, S.C. Chang, M.J. Kim, D.W. Chu, and Y. Ohashi Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial Clinical Infectious Diseases 51 2010 1167 1175
70. S. Bantia, C.D. Parker, S.L. Ananth, L.L. Horn, K. Andries, P. Chand, P.L. Kotian, A. Dehghani, Y. El-Kattan, and T. Lin Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir Antimicrobial Agents and Chemotherapy 45 2001 1162 1167 (Pubitemid 32230997)
71. Y.S. Babu, P. Chand, S. Bantia, P. Kotian, A. Dehghani, Y. El-Kattan, T.H. Lin, T.L. Hutchison, A.J. Elliott, and C.D. Parker BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design Journal of Medicinal Chemistry 43 2000 3482 3486
72. L. Barroso, J. Treanor, L. Gubareva, and F.G. Hayden Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment Antiviral Therapy 10 2005 901 910 (Pubitemid 43076341)
73. J.E. Hernandez, R. Adiga, R. Armstrong, J. Bazan, H. Bonilla, J. Bradley, R. Dretler, M.G. Ison, J.E. Mangino, and S. Maroushek Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States Clinical Infectious Diseases 52 2011 695 706
74. S. Kohno, H. Kida, M. Mizuguchi, and J. Shimada Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection Antimicrobial Agents and Chemotherapy 54 2010 4568 4574
75. S. Kohno, M.Y. Yen, H.J. Cheong, N. Hirotsu, T. Ishida, J.I. Kadota, M. Mizuguchi, H. Kida, and J. Shimada Comparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: a phase III randomized, double-blind study Antimicrobial Agents and Chemotherapy 2011
76. S. Kohno, H. Kida, M. Mizuguchi, N. Hirotsu, T. Ishida, J. Kadota, and J. Shimada Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients Antimicrobial Agents and Chemotherapy 55 2011 2803 2812
77. M.G. Ison, A.J. Mcgeer, D.S. Hui, K. Clezy, B. O'Neil, A. Flynt, J. Elder, T.J. Simon, and W.J. Alexander Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza XI International Symposium on Respiratory Viral Infections 2009
78. M.G. Ison Update on phase 3 trials - IV peramivir XIII International Symposium on Respiratory Viral Infections Rome, Italy 2011
79. D. Birnkrant, and E. Cox The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza The New England Journal of Medicine 361 2009 2204 2207
80. Biocryst reports preliminary results from a phase II clinical trial of peramivir in subjects with acute influenza. In BioCryst Pharmaceuticals, Inc Press Release. September 19, 2009.
81. BioCryst provides peramivir update and reports first quarter 2009 financial results. In BioCryst Pharmaceuticals, Inc Press Release. May 8, 2009.
82. M.P. Malakhov, L.M. Aschenbrenner, D.F. Smee, M.K. Wandersee, R.W. Sidwell, L.V. Gubareva, V.P. Mishin, F.G. Hayden, D.H. Kim, and A. Ing Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection Antimicrobial Agents and Chemotherapy 50 2006 1470 1479
83. A. Moscona, M. Porotto, S. Palmer, C. Tai, L. Aschenbrenner, G. Triana-Baltzer, Q.X. Li, D. Wurtman, S. Niewiesk, and F. Fang A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo The Journal of Infectious Diseases 202 2010 234 241
84. G.B. Triana-Baltzer, M. Babizki, M.C. Chan, A.C. Wong, L.M. Aschenbrenner, E.R. Campbell, Q.X. Li, R.W. Chan, J.S. Peiris, and J.M. Nicholls DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis The Journal of Antimicrobial Chemotherapy 65 2010 275 284
85. R.B. Moss, R. Steigbigel, D. Wurtman, C. Hansen, K. Tranel, M. Cordova, J. Larson, R.L. Sanders, S. Hawley, and T. Li A phase 2A dose-ranging clinical trial of DAS181 for treatment of influenza in healthy adults 51st Intersicence Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois 2011 V-405a
86. Y. Furuta, K. Takahashi, K. Shiraki, K. Sakamoto, D.F. Smee, D.L. Barnard, B.B. Gowen, J.G. Julander, and J.D. Morrey T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections Antiviral Research 82 2009 95 102
87. Y. Furuta, K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, N. Nomura, H. Egawa, and K. Shiraki Mechanism of action of T-705 against influenza virus Antimicrobial Agents and Chemotherapy 49 2005 981 986 (Pubitemid 40327713)
88. F. Hayden Developing new antiviral agents for influenza treatment: what does the future hold? Clinical Infectious Diseases 48 Suppl. 1 2009 S3 S13
89. T.C. Luke, A. Casadevall, S.J. Watowich, S.L. Hoffman, J.H. Beigel, and T.H. Burgess Hark back: passive immunotherapy for influenza and other serious infections Critical Care Medicine 38 2010 e66 e73
90. M.G. Ison, J.W. Gnann Jr., S. Nagy-Agren, J. Treannor, C. Paya, R. Steigbigel, M. Elliott, H.L. Weiss, and F.G. Hayden Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza Antiviral Therapy 8 2003 183 190 (Pubitemid 36960891)
91. J.T. Nguyen, J.D. Hoopes, M.H. Le, D.F. Smee, A.K. Patick, D.J. Faix, P.J. Blair, M.D. de Jong, M.N. Prichard, and G.T. Went Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro PLoS ONE 5 2010 e9332
92. X. Duval, S. van der Werf, T. Blanchon, A. Mosnier, M. Bouscambert-Duchamp, A. Tibi, V. Enouf, C. Charlois-Ou, C. Vincent, and L. Andreoletti Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial PLoS Medicine 7 2010 e1000362
93. P. Astrahan, I. Kass, M.A. Cooper, and I.T. Arkin A novel method of resistance for influenza against a channel-blocking antiviral drug Proteins 55 2004 251 257 (Pubitemid 38437485)
94. A.J. Hay, M.C. Zambon, A.J. Wolstenholme, J.J. Skehel, and M.H. Smith Molecular basis of resistance of influenza A viruses to amantadine The Journal of Antimicrobial Chemotherapy 18 Suppl. B 1986 19 29 (Pubitemid 17199048)
95. A.C. Hurt, H.T. Ho, and I. Barr Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors Expert Review of Anti-infective Therapy 4 2006 795 805 (Pubitemid 44890619)
96. M.G. Ison Anti-influenza therapy: the emerging challenge of resistance Therapy 6 2009 883 891
97. R.A. Bright, D.K. Shay, B. Shu, N.J. Cox, and A.I. Klimov Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States JAMA 295 2006 891 894
98. V.M. Deyde, X. Xu, R.A. Bright, M. Shaw, C.B. Smith, Y. Zhang, Y. Shu, L.V. Gubareva, N.J. Cox, and A.I. Klimov Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide The Journal of Infectious Diseases 196 2007 249 257 (Pubitemid 47047464)
99. E. Bautista, T. Chotpitayasunondh, Z. Gao, S.A. Harper, M. Shaw, T.M. Uyeki, S.R. Zaki, F.G. Hayden, D.S. Hui, and J.D. Kettner Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection The New England Journal of Medicine 362 2010 1708 1719
100. A.N. Abdel-Ghafar, T. Chotpitayasunondh, Z. Gao, F.G. Hayden, D.H. Nguyen, M.D. de Jong, A. Naghdaliyev, J.S. Peiris, N. Shindo, and S. Soeroso Update on avian influenza A (H5N1) virus infection in humans The New England Journal of Medicine 358 2008 261 273
101. R.A. Bright, M.J. Medina, X. Xu, G. Perez-Oronoz, T.R. Wallis, X.M. Davis, L. Povinelli, N.J. Cox, and A.I. Klimov Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern Lancet 366 2005 1175 1181 (Pubitemid 41393595)
102. A.C. Hurt, J.K. Holien, M.W. Parker, and I.G. Barr Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses Drugs 69 2009 2523 2531
103. A. Lackenby, O. Hungnes, S.G. Dudman, A. Meijer, W.J. Paget, A.J. Hay, and M.C. Zambon Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe Euro Surveillance 13 2008
104. T.G. Sheu, V.M. Deyde, R.J. Garten, A.I. Klimov, and L.V. Gubareva Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing Antiviral Research 85 2010 354 360
105. L.V. Gubareva, A.A. Trujillo, M. Okomo-Adhiambo, V.P. Mishin, V.M. Deyde, K. Sleeman, H.T. Nguyen, T.G. Sheu, R.J. Garten, and M.W. Shaw Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro Antiviral Therapy 15 2010 1151 1159
106. D.W. Brookes, S. Miah, A. Lackenby, L. Hartgroves, and W.S. Barclay Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness The Journal of Antimicrobial Chemotherapy 66 2011 466 470
107. F.Y. Aoki, G. Boivin, and N. Roberts Influenza virus susceptibility and resistance to oseltamivir Antiviral Therapy 12 2007 603 616 (Pubitemid 47235503)
108. L.V. Gubareva Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors Virus Research 103 2004 199 203 (Pubitemid 38649080)
109. M. Matrosovich, T. Matrosovich, J. Carr, N.A. Roberts, and H.D. Klenk Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors Journal of Virology 77 2003 8418 8425 (Pubitemid 36871470)
110. M. Potier, L. Mameli, M. Belisle, L. Dallaire, and S.B. Melancon Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D- N-acetylneuraminate) substrate Analytical Biochemistry 94 1979 287 296 (Pubitemid 9173017)
111. V.M. Deyde, T.G. Sheu, A.A. Trujillo, M. Okomo-Adhiambo, R. Garten, A.I. Klimov, and L.V. Gubareva Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing Antimicrobial Agents and Chemotherapy 54 2010 1102 1110
112. G.B. Triana-Baltzer, R.L. Sanders, M. Hedlund, K.A. Jensen, L.M. Aschenbrenner, J.L. Larson, and F. Fang Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181 The Journal of Antimicrobial Chemotherapy 66 2011 15 28
113. D.A. Boltz, J.R. Aldridge Jr., R.G. Webster, and E.A. Govorkova Drugs in development for influenza Drugs 70 2010 1349 1362